Consolidated Balance Sheets December 31, 2001 2000 (in thousands of dollars) Assets Current assets: Cash and cash equivalents $ 5,772 $ 20,300 Marketable securities 99,279 97,223 Related parties receivables 465 104 Prepaid expenses and other current assets 441 222 Total current assets 105,957 117,849 Property and equipment, net 575 593 Investment in other companies 600 — $ 107,132 $118,442 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 894 $ 1,304 Accrued clinical trials expenses 2,156 432 Other accrued liabilities 714 727 Deferred contract revenue 2,000 — Total current liabilities 5,764 2,463 Commitments: Minority interest—Series B preferred stock of Ingenex, Inc. 1,241 1,241 Stockholders’ equity: Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, issuable in series: Convertible Series C, 222,400 shares designated, 222,400 shares issued and outstanding,  with an aggregate liquidation value of $2,000 at December 31, 2001 and 2000 — — Common stock, at amounts paid in, $0.001 par value per share; 50,000,000 shares authorized,  27,641,770 and 27,233,754 shares issued and outstanding at December 31, 2001 and 2000,  respectively 191,684 190,763 Additional paid-in capital 9,017 8,744 Deferred compensation (795) (1,254) Accumulated deficit (101,670) (84,206) Accumulated other comprehensive income 1,891 691 Total stockholders’ equity 100,127 114,738 $ 107,132 $118,442 See accompanying notes. Eighteen